Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $26,290.00 |
|---|---|
| Enterprise Value | $-382.00 |
| Earnings per Share | $-0.01 |
| Beta | 0.38 |
| Outstanding Shares | 131,448,444 |
| P/E Ratio | -0.03 |
|---|---|
| PEG | 0.4 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 64.15 |
| Debt to Equity | 0.36 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemi...